Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
NCT02684071
Terminated
The purpose of this research study is to test an experimental treatment method for recurrent or progressive brain tumors in children aged from 0-22 years. The use of methotrexate and chemotherapy (topotecan and cyclophosphamide) is experimental in this study. This means that their use by themselves or together has not been approved by the U.S. Food and Drug Administration for this usage.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
01/07/2020
Locations: Nicklaus Children's Hospital, Miami, Florida
Conditions: Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes, Metastatic Malignant Neoplasm to the Leptomeninges
Register for Updates
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00602836
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stop the growth of cancer cells by blocking some... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/07/2020
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +2 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
NCT01839097
Completed
The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/31/2019
Locations: Yale University, New Haven, Connecticut +7 locations
Conditions: Peripheral T-cell Lymphoma
Register for Updates
Bone Marrow Transplantation in Treating Patients With Leukemia
NCT00006451
Withdrawn
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Randomized phase II/III trial to determine the effectiveness of bone marrow transplantation in treating patients who have leukemia.
Gender:
ALL
Ages:
45 years and below
Trial Updated:
12/31/2019
Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota
Conditions: Graft Versus Host Disease, Leukemia, Lymphoma
Register for Updates
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
NCT03935347
Withdrawn
This phase II trial studies how well autologous tumor infiltrating lymphocytes (LN-145) and pembrolizumab work in treating patients with transitional cell cancer that cannot be removed by surgery or has spread to other places in the body and have failed cisplatin-based chemotherapy. LN-145 is made up of specialized immune cells called lymphocytes or T cells that are taken from a patient's tumor, grown in a manufacturing facility and infused back into the preconditioned patient to attack the tumo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2019
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
Register for Updates
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
NCT01146834
Completed
This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies. Up to 180 patients will be enrolled. Patients eligible for treatment will be randomized to one of the three following mobilization regimens: Arm A = VELCADE, CYCLOPHOSPHAMIDE, \& G-CSF Arm B = VELCADE \& G-CSF Arm C = CYCLOPHOSPHAMIDE \& G-CSF Arm D = PLERIXAFOR \& G-CSF Arm E = PLERIXAFOR, VELCADE,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2019
Locations: Emory University, Atlanta, Georgia +4 locations
Conditions: Multiple Myeloma
Register for Updates
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
NCT00616122
Terminated
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of sunitinib when given together with... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/18/2019
Locations: University of California, San Francisco, San Francisco, California
Conditions: Breast Cancer
Register for Updates
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
NCT00723099
Completed
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from an unrelated donor, that do not exactly match the patient's blood, are infused into the patien... Read More
Gender:
ALL
Ages:
69 years and below
Trial Updated:
12/17/2019
Locations: University of Colorado Hospital, Aurora, Colorado +5 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Indolent Non-Hodgkin Lymphoma, Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, Refractory Follicular Lymphoma, Refractory Hodgkin Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Non-Hodgkin Lymphoma
Register for Updates
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
NCT01445522
Completed
Background: * Cyclophosphamide (CP) is a drug approved by the Food and Drug Administration for the treatment of certain cancers. It works by causing DNA damage, resulting in cell death, including cancer cells. * ABT-888 is an experimental drug that has been given to a small number of patients. It works by preventing DNA repair in tumor cells. Objectives: * To test the safety of the combination of ABT-888 and CP, and to determine the dose of each drug that can be given together to patients wit... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
12/14/2019
Locations: City of Hope National Medical Center, Duarte, California +1 locations
Conditions: Neoplasms, Lymphoma
Register for Updates
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
NCT02465983
Terminated
This is a study in which pancreatic cancer patients receive a combination therapy with CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide. CART-meso cells are patients' own T cells that were modified in the laboratory to express a receptor specific to the mesothelin protein. CART19 cells are patients' own T cells that were modified in the laboratory to express a receptor specific to a protein called CD19. The CD19 protein is expressed on white blood B cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2019
Locations: University of California, San Francisco, San Francisco, California
Conditions: Pancreatic Cancer
Register for Updates
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
NCT02145039
Terminated
This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the treatment of patients with advanced and/or high risk diseases.
Gender:
ALL
Ages:
74 years and below
Trial Updated:
12/12/2019
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia
Register for Updates
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
NCT00581776
Completed
Patients will receive Rituximab, Bortezomib, cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone in three week intervals for 6 cycles; then rituximab consolidation (weekly x 4) , then one dose of rituximab every 12 weeks until 5 years or disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2019
Locations: University Of Wisconsin Cancer Center, Madison, Wisconsin
Conditions: Mantle Cell Lymphoma
Register for Updates